JPRN-jRCT2032190209已完成3 期
A Multicenter, Prospective, Open Label, Single-Arm Study of a Novel Pain Management Device, AT-04, in Patients with Acute Low Back Pain
Miki Kenji0 个研究点目标入组 30 人开始时间: 2020年2月13日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
The efficacy and safety of AT-04 in clinical use were demonstrated and it was judged the goal of this clinical study was achieved.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 80age old(—)
- 性别
- All
入选标准
- •(1) Age: Patients aged >= 20 to < 80 years (at the time of informed consent)
- •(2) Patients with VAS value >= 40 mm and time from onset of >= 4 weeks to < 3 months
- •(3) Patients who have not received the treatment for acute low back pain or who have received the treatment for acute low back pain without any change in the treatment regimen (including the prescription, dosage and administration) during the 14 days before formal registration
- •(4) Patients with no changes in the degree of pain during the 14 days before formal registration
- •(5) Patients not requiring hospitalization for treatment
- •(6) Patients for whom written consent can be obtained directly from the patient
排除标准
- •(1) Patients who have findings of spinal disease other than low back pain and who also have pain attributable to the disease
- •(2) Patients with a history of surgery for spinal or lumbar disease
- •(3) Patients with psychiatric disease that is known to affect the measurement of pain
- •(4) Patients for whom treatment of underlying diseases clearly causing pain such as trauma and arthritis (rheumatic, osteoarthritis and infectious) should be prioritized
- •(5) Patients who are using life-supporting medical electrical equipment such as a heart-lung machine or a pacemaker
- •(6) Patients using wearable medical electrical equipment such as electrocardiograph
- •(7) Patients with a history of drug abuse (including alcohol)
- •(8) Patients with intractable pain whose VAS value is 40 mm or higher despite simultaneous administration of 3 or more of the following drugs: weak opioids such as tramadol, pregabalin, Cymbalta, or Tryptanol
- •(9) Patients who are participating in clinical studies of other drugs or medical devices
- •(10) Patients requiring hospitalization for treatment
- •(11) Patients with dementia severely interfering with daily life
- •(12) Women who wish to become pregnant or are pregnant or lactating (a pregnancy test should be performed if there is a possibility of pregnancy)
研究者
相似试验
已完成
1 期
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPCProstate CancerNCT00286793Ascenta Therapeutics76
终止
2 期
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)IgA NephropathyIgANNCT05125068Eledon Pharmaceuticals24
已完成
1 期
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung CancerSmall Cell Lung CancerNCT00397293Ascenta Therapeutics36
已完成
4 期
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)Juvenile Idiopathic ArthritisNCT03301883Hoffmann-La Roche62
已完成
3 期
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-AmethistaCarcinoma, HepatocellularNCT04487067Hoffmann-La Roche152
